Skip to main content
Yantai Zhenghai Bio-Tech Co., Ltd. logo

Yantai Zhenghai Bio-Tech Co., Ltd. — Investor Relations & Filings

Ticker · 300653 ISIN · CNE100002NZ1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 970 across all filing types
Latest filing 2021-04-28 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300653

About Yantai Zhenghai Bio-Tech Co., Ltd.

https://www.zhbio.com

Yantai Zhenghai Bio-Tech Co., Ltd. specializes in the research, development, production, and sale of regenerative medicine materials. The company focuses on tissue engineering and biomaterials to provide solutions for clinical repair and functional reconstruction. Its core product portfolio includes the Heal-All oral repair membrane, absorbable hard cerebral (spinal) membrane patches, and skin repair membranes. These products are widely utilized in stomatology, neurosurgery, and orthopedics. The company leverages advanced processing technologies to ensure biocompatibility and safety in its medical devices. By integrating research with clinical needs, it develops innovative bone repair materials and other biological scaffolds designed to facilitate natural tissue regeneration.

Recent filings

Filing Released Lang Actions
2021年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2021 年第一季度报告全文" which translates to "2021 First Quarter Report Full Text." It contains detailed financial data including income statement, balance sheet, cash flow statement, and management discussion and analysis for the first quarter of 2021. The document includes comprehensive financial metrics, shareholder information, business review, risk factors, and fundraising usage details. The length is substantial (15,000 characters) and it contains actual financial statements and substantive financial data for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-28 Chinese
关于变更公司办公地址的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement about the change of the company's office address. It includes the old and new addresses, contact information, and a statement ensuring the accuracy of the disclosure. There is no financial data, no mention of a report or meeting, no voting results, no management changes, no legal proceedings, or other specific report content. The document is an official announcement related to company information but does not fit into categories like Annual Report, Interim Report, or Management Reports. It is not a report publication announcement since it does not mention any report release. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The confidence is high given the clear nature of the announcement and lack of other report characteristics.
2021-04-28 Chinese
第二届监事会第十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is titled '监事会决议公告' which translates to 'Supervisory Board Resolution Announcement'. It details the meeting of the supervisory board held on April 28, 2021, including attendance and the approval of the company's 2021 first quarter report. The document states that the supervisory board reviewed and approved the first quarter report but does not contain the report itself. It also references that the full 2021 first quarter report is disclosed on the official regulatory website. The document length is short (902 characters) and serves as an announcement of the supervisory board's resolution regarding the quarterly report, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and confirmation of the supervisory board's review and approval, rather than the actual Interim/Quarterly Report (IR).
2021-04-28 Chinese
关于召开2020年年度股东大会的提示性公告
AGM Information Classification · 95% confidence The document is titled as a "提示性公告" (notice or reminder announcement) regarding the convening of the 2020 Annual General Meeting (AGM) of shareholders for the company 烟台正海生物科技股份有限公司. It details the date, time, location, agenda items, voting procedures, and registration methods for the AGM. The document includes information about the proposals to be voted on, including board and supervisory reports, financial reports, profit distribution plans, election of directors and supervisors, and other governance matters. It does not contain the actual reports or financial statements but rather serves as a notice to shareholders about the upcoming meeting and how to participate. The document length is 9249 characters, which is substantial but the content is clearly an announcement for the AGM rather than the AGM materials themselves or the voting results. Therefore, this fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM itself.
2021-04-27 Chinese
关于控股股东、实际控制人的一致行动人减持股份的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding the planned reduction of shares held by a controlling shareholder's concerted party. It details the shareholder's identity, shareholding percentages, planned reduction quantities, timing, and compliance with regulatory requirements. The document references specific regulations governing shareholder share reduction disclosures and includes risk warnings related to the share reduction plan. The document length is 3306 characters, which is relatively short and primarily serves as an announcement of a planned share reduction rather than a full report or financial statement. It does not contain financial data or detailed financial analysis. Therefore, it fits the category of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels, including pre-disclosure of share reduction plans by major shareholders or their concerted parties.
2021-04-23 Chinese
关于公司产品进入创新医疗器械特别审批程序的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a product entering a special approval procedure for innovative medical devices. It includes details about the product, regulatory approval status, and potential impact on the company. The document is short (1194 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an official announcement about regulatory progress and product approval status, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-04-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.